Tempus AI, Inc. recently launched a sophisticated new service today. This automated active follow-up service supports guideline-concordant care effectively. It specifically places patients on a specialized track for precision medicine. Consequently, clinicians receive ongoing therapy monitoring through the Hub portal. This secure, AI-enabled physician portal delivers context-aware notifications seamlessly.
Initial genomic reports often become outdated very quickly. This happens because FDA approvals and NCCN guidelines evolve rapidly. Moreover, the circumstances of patients change throughout their treatment. Tempus addresses this major challenge with its automated active follow-up system.
They automatically surface updated therapy recommendations for patients. These updates appear when clinical guidelines change over time. Alternatively, they emerge when new therapeutic options become available. Crucially, this process does not require a new patient sample. Therefore, patient insights remain as current as modern science. This supports evidence-based decision-making for every patient.
Bridging the Medical Innovation Gap
Modern oncology practice moves at a very fast pace. Currently, drugs receive approval much faster than before. Sometimes, a tumor harbors a specific targetable alteration. However, the treatment may get approved after the sequencing ends. The automated active follow-up creates a vital clinical safety net. It specifically bridges the gap between sequencing and drug approvals. It ensures genomic insights remain a living resource for doctors. By using this automated active follow-up, physicians stay informed. Precision medicine benefits from these real-time digital updates.
“The reality in modern oncology practice is that drugs are getting approved and treatments are changing at a much faster rate than before,” said Ezra Cohen, MD, Chief Medical Officer of Oncology at Tempus. “Many times, this creates a situation where a patient’s tumor harbors a targetable alteration but the treatment gets approved after sequencing is performed. We launched this automated clinical update service with the goal of bridging the gap between timing of sequencing and drug approval by providing a clinical safety net that keeps pace with the speed of medical innovation. By moving to a model of ‘active follow-up,’ we ensure that genomic insights remain a living resource rather than a static report.”
Explore Health Tech Insiders for the latest medical innovations and reliable strategic insights driving the future of technology-driven healthcare transformation.
News Source: Businesswire.com
